EpilepsyGTx, a London, UK-based biotechnology company focused on research and development of gene therapies to treat focal refractory epilepsy, raised $10M in Seed funding.
The round was led by UCL Technology Fund, with participation from Health Technology Holding.
The company intends to use the funds to complete the preclinical studies for its lead gene therapy program EPY201, and to prepare a first-in-human, Phase 1/2a clinical study with EPY201 in focal refractory epilepsy.
Led by CEO Nicolas Koebel, EpilepsyGTx provides an approach delivering a single dose of gene therapy directly to the seizure focus, in a surgical procedure that takes place in a hospital. During the procedure, a very thin cannula with a diameter of about 1-2 millimetres (that is, thinner than a grain of rice) is inserted into the seizure focus to deliver a volume of about 1 millilitre (or ml) of gene therapy. Its approach does not require the permanent destruction of cerebral tissue, in contrast to resective surgery or laser ablation (or LITT). Furthermore, it only treats the seizure focus, in contrast to antiseizure medicines which are distributed throughout the brain and the entire body of patients.
FinSMEs
24/06/2024